

# Lars Ny

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9031319/publications.pdf>

Version: 2024-02-01

93  
papers

4,042  
citations

136740

32  
h-index

123241

61  
g-index

99  
all docs

99  
docs citations

99  
times ranked

5362  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. <i>Melanoma Research</i> , 2022, 32, 241-248.	0.6	9
2	Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. <i>European Journal of Surgical Oncology</i> , 2022, 48, 320-325.	0.5	18
3	PD-1 inhibitor therapy of basal cell carcinoma with pulmonary metastasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 70-73.	1.3	3
4	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 702.	1.7	3
5	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. <i>European Journal of Cancer</i> , 2022, 169, 210-222.	1.3	12
6	Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. <i>Acta Oncologica</i> , 2022, 61, 869-873.	0.8	1
7	Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage II Melanoma Patients at Risk of Disease Relapse. <i>Cancers</i> , 2022, 14, 2854.	1.7	9
8	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9569-9569.	0.8	0
9	Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA9509-LBA9509.	0.8	6
10	Immune Checkpoint Inhibitor-Induced Polymyositis and Myasthenia Gravis with Fatal Outcome. <i>Case Reports in Oncology</i> , 2021, 13, 1252-1257.	0.3	8
11	Surgery of metastatic melanoma after systemic therapy – the SUMMIST trial: study protocol for a randomized controlled trial. <i>Acta Oncologica</i> , 2021, 60, 52-55.	0.8	5
12	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021, 31, 181-185.	0.6	14
13	Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9504-9504.	0.8	23
14	Plasma thymidine kinase activity (TKa) as a novel prognostic biomarker in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9556-9556.	0.8	0
15	Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. , 2021, 9, e002732.		12
16	The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. <i>Nature Communications</i> , 2021, 12, 5155.	5.8	85
17	Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma. <i>American Journal of Pathology</i> , 2021, 191, 2023-2038.	1.9	13
18	Clinical outcomes in cancer patients with COVID-19 in Sweden. <i>Acta Oncologica</i> , 2021, 60, 1572-1579.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Reply to Comment on Katsarelis, D., et al. "The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma" A Nation-Wide Swedish Population-Based Retrospective Register Study. <i>Cancers</i> 2020, 12, 3228. <i>Cancers</i> , 2021, 13, 92.	1.7	1
20	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
21	The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma" A Nation-Wide Swedish Population-Based Retrospective Register Study. <i>Cancers</i> , 2020, 12, 3228.	1.7	9
22	Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection. <i>Case Reports in Oncology</i> , 2020, 13, 478-484.	0.3	15
23	Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. <i>Annals of Oncology</i> , 2020, 31, 266-273.	0.6	26
24	Radiation of the urinary bladder attenuates the development of lipopolysaccharide-induced cystitis. <i>International Immunopharmacology</i> , 2020, 83, 106334.	1.7	3
25	Molecular profiling of driver events in metastatic uveal melanoma. <i>Nature Communications</i> , 2020, 11, 1894.	5.8	108
26	<i>BRAF</i> mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 833-844.	0.8	48
27	Surgery for gastrointestinal metastases of malignant melanoma " a retrospective exploratory study. <i>World Journal of Surgical Oncology</i> , 2019, 17, 123.	0.8	8
28	Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study). <i>Annals of Oncology</i> , 2019, 30, v907.	0.6	8
29	Real-world data on PD-1 inhibitor therapy in metastatic melanoma. <i>Acta Oncologica</i> , 2019, 58, 962-966.	0.8	26
30	A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. <i>Annals of Surgical Oncology</i> , 2019, 26, 2839-2845.	0.7	16
31	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. <i>BMC Cancer</i> , 2019, 19, 415.	1.1	49
32	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. <i>Cancer Research</i> , 2019, 79, 899-904.	0.4	84
33	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
34	Abstract 3185: CAR-T cells can eradicate human uveal melanoma and immune-therapy resistant malignant melanoma in IL-2 transgenic NOD/SCID IL2 receptor gamma knockout mice. , 2019, , .		1
35	Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. <i>Lancet Oncology</i> , The, 2018, 19, e327.	5.1	22
36	A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. <i>Cell Death and Disease</i> , 2018, 9, 810.	2.7	38

#	ARTICLE	IF	CITATIONS
37	BRAF mutation as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21566-e21566.	0.8	8
38	Mouse avatars take off as cancer models. <i>Nature</i> , 2018, 562, 192-192.	13.7	2
39	Hyperbaric oxygen treatment reverses radiation induced pro-fibrotic and oxidative stress responses in a rat model. <i>Free Radical Biology and Medicine</i> , 2017, 103, 248-255.	1.3	33
40	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. <i>Nature Communications</i> , 2017, 8, 707.	5.8	123
41	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. <i>Cell Death and Disease</i> , 2017, 8, e2982-e2982.	2.7	17
42	Adjuvant therapies for malignant melanoma. <i>British Journal of Surgery</i> , 2016, 103, 1095-1096.	0.1	2
43	Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. <i>Annals of Surgical Oncology</i> , 2016, 23, 1327-1334.	0.7	24
44	Downregulation of toll-like receptor 4 and $\alpha\beta$ following irradiation of the rat urinary bladder. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 698-705.	0.9	19
45	Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. <i>Oncotarget</i> , 2016, 7, 23801-23811.	0.8	13
46	Abstract 642: Hypoxia-regulated gene expression explains differences between cell line-derived xenografts and patient-derived xenografts. , 2016, , .		0
47	Abstract B38: Melanoma patient-derived xenografts accurately models the disease and develop fast enough to guide treatment decisions. , 2015, , .		0
48	Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. <i>Nature Genetics</i> , 2014, 46, 1258-1263.	9.4	269
49	Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 317.	0.7	33
50	Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. <i>Oncotarget</i> , 2014, 5, 9609-9618.	0.8	62
51	Abstract 1215: Identifying new treatment options for metastatic melanoma using patient derived xenografts: Defining the role of Pim kinases. , 2014, , .		0
52	Bacterial flora of the human oral cavity, and the upper and lower esophagus. <i>Ecological Management and Restoration</i> , 2013, 26, 84-90.	0.2	94
53	Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 274-284.	0.6	71
54	Nitric oxide and endothelin-1 release after one-lung ventilation during thoracoabdominal esophagectomy. <i>Ecological Management and Restoration</i> , 2013, 26, 853-858.	0.2	2

#	ARTICLE	IF	CITATIONS
55	The effects of a novel metabotropic glutamate receptor 5 antagonist (<sc>AZD</sc>2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1231-1242.	1.9	39
56	Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1113-1122.	1.9	123
57	Risk of clinically relevant bleeding in warfarin-treated patients' influence of SSRI treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 412-416.	0.9	59
58	A magnetic resonance imaging study of intestinal dilation in <i>Trypanosoma cruzi</i> -infected mice deficient in nitric oxide synthase. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 760-7.	0.6	12
59	Reporting of adverse drug reactions may be influenced by feedback to the reporting doctor. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 505-508.	0.8	18
60	Epithelial barrier integrity and intraluminal nitric oxide production in response to acid perfusion of the ferret oesophagus. <i>Acta Physiologica Scandinavica</i> , 2005, 183, 211-218.	2.3	2
61	Acid Challenge to the Esophageal Mucosa: Effects on Local Nitric Oxide Formation and Its Relation to Epithelial Functions. <i>Digestive Diseases and Sciences</i> , 2005, 50, 640-648.	1.1	12
62	Acid Challenge to the Human Esophageal Mucosa: Effects on Epithelial Architecture in Health and Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1488-1496.	1.1	29
63	Effects of Dietary Nitrate on Oesophageal Motor Function and Gastro-Oesophageal Acid Exposure in Healthy Volunteers and Reflux Patients. <i>Digestion</i> , 2003, 68, 49-56.	1.2	10
64	Impaired relaxation of stomach smooth muscle in mice lacking cyclic GMP-dependent protein kinase I. <i>British Journal of Pharmacology</i> , 2000, 129, 395-401.	2.7	53
65	CHOLINERGIC NERVES IN HUMAN CORPUS CAVERNOSUM AND SPONGIOSUM CONTAIN NITRIC OXIDE SYNTHASE AND HEME OXYGENASE. <i>Journal of Urology</i> , 2000, 164, 868-875.	0.2	95
66	CHOLINERGIC NERVES IN HUMAN CORPUS CAVERNOSUM AND SPONGIOSUM CONTAIN NITRIC OXIDE SYNTHASE AND HEME OXYGENASE. <i>Journal of Urology</i> , 2000, 164, 868-875.	0.2	29
67	The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. <i>EMBO Journal</i> , 1999, 18, 37-48.	3.5	304
68	Localization and activity of nitric oxide synthases in the gastrointestinal tract of <i>Trypanosoma cruzi</i> -infected mice. <i>Journal of Neuroimmunology</i> , 1999, 99, 27-35.	1.1	16
69	The nitric oxide pathway in pig isolated calyceal smooth muscle. <i>Neurourology and Urodynamics</i> , 1999, 18, 673-685.	0.8	5
70	Heme oxygenase-1, heme oxygenase-2 and biliverdin reductase in peripheral ganglia from rat, expression and plasticity. <i>Neuroscience</i> , 1999, 95, 821-829.	1.1	21
71	CO-LOCALIZATION OF CARBON MONOXIDE AND NITRIC OXIDE SYNTHESIZING ENZYMES IN THE HUMAN URETHRAL SPHINCTER. <i>Journal of Urology</i> , 1999, 161, 1968-1972.	0.2	46
72	CO-LOCALIZATION OF CARBON MONOXIDE AND NITRIC OXIDE SYNTHESIZING ENZYMES IN THE HUMAN URETHRAL SPHINCTER. <i>Journal of Urology</i> , 1999, , 1968-1972.	0.2	2

#	ARTICLE	IF	CITATIONS
73	Defective smooth muscle regulation in cGMP kinase I-deficient mice. <i>EMBO Journal</i> , 1998, 17, 3045-3051.	3.5	466
74	Mediators and mechanisms of relaxation in rabbit urethral smooth muscle. <i>British Journal of Pharmacology</i> , 1998, 123, 617-624.	2.7	41
75	NITRIC OXIDE SYNTHASE IN THE HETEROGENEOUS POPULATION OF INTRAMURAL STRIATED MUSCLE FIBRES OF THE HUMAN MEMBRANOUS URETHRAL SPHINCTER. <i>Journal of Urology</i> , 1998, 159, 1091-1096.	0.2	54
76	The Nitric Oxide Synthase/ Nitric Oxide and Heme Oxygenase/ Carbon Monoxide Pathways in the Human Ureter. <i>European Urology</i> , 1998, 33, 214-221.	0.9	28
77	Morphological relations between haem oxygenases, NO-synthase and VIP in the canine and feline gastrointestinal tracts. <i>Journal of the Autonomic Nervous System</i> , 1997, 65, 49-56.	1.9	43
78	Pitfalls using metalloporphyrins in carbon monoxide research. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 193-195.	4.0	95
79	Pitfalls using metalloporphyrins in carbon monoxide research. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 193-195.	4.0	129
80	Inhibition of stimulated cyclic AMP production by multiple neuropeptide Y receptors in the rat brainstem. <i>Neuroscience Letters</i> , 1997, 221, 113-116.	1.0	5
81	$\hat{I}\pm$ -Latrotoxin-induced transmitter release in feline oesophageal smooth muscle; focus on nitric oxide and vasoactive intestinal peptide. <i>British Journal of Pharmacology</i> , 1997, 120, 31-38.	2.7	10
82	Carbon monoxide-induced relaxation and distribution of haem oxygenase isoenzymes in the pig urethra and lower oesophagogastric junction. <i>British Journal of Pharmacology</i> , 1997, 120, 312-318.	2.7	58
83	Neurotransmitter release evoked by $\hat{I}\pm$ -latrotoxin in the smooth muscle of the female pig urethra. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997, 356, 151-158.	1.4	12
84	Several neuropeptide Y receptors modulate cyclic AMP production in the rat brainstem. <i>Proceedings of the Western Pharmacology Society</i> , 1997, 40, 21-3.	0.1	0
85	Localization and activity of haem oxygenase and functional effects of carbon monoxide in the feline lower oesophageal sphincter. <i>British Journal of Pharmacology</i> , 1996, 118, 392-399.	2.7	53
86	Modulation of carbon monoxide production and enhanced spatial learning by tin protoporphyrin. <i>NeuroReport</i> , 1995, 6, 1369-1372.	0.6	24
87	Carbon monoxide as a putative messenger molecule in the feline lower oesophageal sphincter of the cat. <i>NeuroReport</i> , 1995, 6, 1389-1393.	0.6	30
88	Nitric oxide pathway in cat esophagus: localization of nitric oxide synthase and functional effects. <i>American Journal of Physiology - Renal Physiology</i> , 1995, 268, G59-G70.	1.6	24
89	Distribution and effects of pituitary adenylate cyclase activating peptide in cat and human lower oesophageal sphincter. <i>British Journal of Pharmacology</i> , 1995, 116, 2873-2880.	2.7	31
90	Factors involved in the relaxation of female pig urethra evoked by electrical field stimulation. <i>British Journal of Pharmacology</i> , 1995, 116, 1599-1604.	2.7	56

#	ARTICLE	IF	CITATIONS
91	Inhibition by zinc protoporphyrin of receptor-mediated relaxation of the rat aorta in a manner distinct from inhibition of haem oxygenase. <i>British Journal of Pharmacology</i> , 1995, 115, 186-190.	2.7	36
92	Nitric oxide synthase-containing, peptide-containing, and acetylcholinesterase-positive nerves in the cat lower oesophagus. <i>The Histochemical Journal</i> , 1994, 26, 721-733.	0.6	47
93	The role of the L-arginine/nitric oxide pathway for relaxation of the human lower oesophageal sphincter. <i>Acta Physiologica Scandinavica</i> , 1993, 149, 451-459.	2.3	49